Cargando…
Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19
During the COVID-19 pandemic, many consumers increased their use of supplements that claimed to support immune health, including Ayurvedic preparations. The goal of this study was to analyze labeling compliance and online claims for Ayurvedic herbal supplements associated with the purported treatmen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901855/ https://www.ncbi.nlm.nih.gov/pubmed/36778101 http://dx.doi.org/10.1016/j.foodcont.2023.109673 |
_version_ | 1784883111923810304 |
---|---|
author | Jordan, Chevon R. Harris, Calin M. Miranda, Miranda I. Kim, Diane Y. Hellberg, Rosalee S. |
author_facet | Jordan, Chevon R. Harris, Calin M. Miranda, Miranda I. Kim, Diane Y. Hellberg, Rosalee S. |
author_sort | Jordan, Chevon R. |
collection | PubMed |
description | During the COVID-19 pandemic, many consumers increased their use of supplements that claimed to support immune health, including Ayurvedic preparations. The goal of this study was to analyze labeling compliance and online claims for Ayurvedic herbal supplements associated with the purported treatment of COVID-19. The physical product labels for 51 herbal supplements labeled as ginger, tulsi/holy basil, amla, vacha/calamus root, guduchi/giloy, cinnamon, ashwagandha, tribulus, or turmeric were assessed for U.S. regulatory compliance. Disease claims, structure/function claims, and general well-being claims were also examined. The online listings for products purchased online (n = 42) were examined for claims and for the presence of the required legal disclaimer. Collectively, 61% of products had at least one instance of noncompliance on the physical label. The most common violations included missing/noncompliant disclaimer (33%), noncompliant “Supplement Facts” label (29%), noncompliant statement of identity (27%) and noncompliant domestic mailing address or phone number (25%). Structure/function claims occurred more frequently in the online product listings (average of 5 claims per product) compared to the physical labels (average of 2 claims per product). Disease claims were observed for 38% of online product listings and on 8% of physical labels. The use of disease claims on herbal supplements is a significant concern for public health because it may lead consumers to delay seeking professional treatment for life-threatening diseases. Overall, this study revealed a lack of labeling compliance among Ayurvedic herbal supplements and a need for greater scrutiny and monitoring of online product listings. |
format | Online Article Text |
id | pubmed-9901855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99018552023-02-07 Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 Jordan, Chevon R. Harris, Calin M. Miranda, Miranda I. Kim, Diane Y. Hellberg, Rosalee S. Food Control Article During the COVID-19 pandemic, many consumers increased their use of supplements that claimed to support immune health, including Ayurvedic preparations. The goal of this study was to analyze labeling compliance and online claims for Ayurvedic herbal supplements associated with the purported treatment of COVID-19. The physical product labels for 51 herbal supplements labeled as ginger, tulsi/holy basil, amla, vacha/calamus root, guduchi/giloy, cinnamon, ashwagandha, tribulus, or turmeric were assessed for U.S. regulatory compliance. Disease claims, structure/function claims, and general well-being claims were also examined. The online listings for products purchased online (n = 42) were examined for claims and for the presence of the required legal disclaimer. Collectively, 61% of products had at least one instance of noncompliance on the physical label. The most common violations included missing/noncompliant disclaimer (33%), noncompliant “Supplement Facts” label (29%), noncompliant statement of identity (27%) and noncompliant domestic mailing address or phone number (25%). Structure/function claims occurred more frequently in the online product listings (average of 5 claims per product) compared to the physical labels (average of 2 claims per product). Disease claims were observed for 38% of online product listings and on 8% of physical labels. The use of disease claims on herbal supplements is a significant concern for public health because it may lead consumers to delay seeking professional treatment for life-threatening diseases. Overall, this study revealed a lack of labeling compliance among Ayurvedic herbal supplements and a need for greater scrutiny and monitoring of online product listings. Elsevier Ltd. 2023-06 2023-02-06 /pmc/articles/PMC9901855/ /pubmed/36778101 http://dx.doi.org/10.1016/j.foodcont.2023.109673 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Jordan, Chevon R. Harris, Calin M. Miranda, Miranda I. Kim, Diane Y. Hellberg, Rosalee S. Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 |
title | Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 |
title_full | Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 |
title_fullStr | Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 |
title_full_unstemmed | Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 |
title_short | Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19 |
title_sort | labeling compliance and online claims for ayurvedic herbal supplements on the u.s. market associated with the purported treatment of covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901855/ https://www.ncbi.nlm.nih.gov/pubmed/36778101 http://dx.doi.org/10.1016/j.foodcont.2023.109673 |
work_keys_str_mv | AT jordanchevonr labelingcomplianceandonlineclaimsforayurvedicherbalsupplementsontheusmarketassociatedwiththepurportedtreatmentofcovid19 AT harriscalinm labelingcomplianceandonlineclaimsforayurvedicherbalsupplementsontheusmarketassociatedwiththepurportedtreatmentofcovid19 AT mirandamirandai labelingcomplianceandonlineclaimsforayurvedicherbalsupplementsontheusmarketassociatedwiththepurportedtreatmentofcovid19 AT kimdianey labelingcomplianceandonlineclaimsforayurvedicherbalsupplementsontheusmarketassociatedwiththepurportedtreatmentofcovid19 AT hellbergrosalees labelingcomplianceandonlineclaimsforayurvedicherbalsupplementsontheusmarketassociatedwiththepurportedtreatmentofcovid19 |